Gas chromatography-mass spectrometry assay for the simultaneous quantification of drugs of abuse in human placenta at 12th week of gestation

Forensic Science International

Volumn 196, Issue 1-3, 2010, Pages 38-42

  Joya, Xavier ^a,b,c   Pujadas, Mitona ^a,d   Falcón, María ^e   Civit, Ester ^a   Garcia Algar, Oscar ^a,b,c   Vall, Oriol ^a,b,c   Pichini, Simona ^f   Luna, Aurelio ^e   de la Torre, Rafael ^a,d,g  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e UNIVERSITY OF MURCIA   (Spain)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Drugs of abuse; Gas chromatography mass spectrometry; Interruption of pregnancy; Placenta; Prenatal exposure

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; BENZOYLECGONINE; COCAINE; COTININE; METHAMPHETAMINE; MORPHINE; NICOTINE; TETRAHYDROCANNABINOLIC ACID;

ACCURACY; ARTICLE; CHEMICAL ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABUSE; FETUS; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN TISSUE; MASS FRAGMENTOGRAPHY; PLACENTA; PLACENTAL TRANSFER; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 76549091827     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2009.12.044     Document Type: Article

References (20)

1. Lozano J., et al. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther. Drug Monit. 29 6 (2007) 711-734
2. Llaquet H., et al. Biological matrices for the evaluation of exposure to environmental tobacco smoke during prenatal life and childhood. Anal. Bioanal. Chem. (2009)
3. Ostrea Jr. E.M., et al. Drug screening of meconium in infants of drug-dependent mothers: an alternative to urine testing. J. Pediatr. 115 3 (1989) 474-477
4. Moore C., Negrusz A., and Lewis D. Determination of drugs of abuse in meconium. J. Chromatogr. B: Biomed. Sci. Appl. 713 1 (1998) 137-146
5. Klein J., Karaskov T., and Koren G. Clinical applications of hair testing for drugs of abuse-the Canadian experience. Forensic Sci. Int. 107 1-3 (2000) 281-288
6. Nanovskaya T., et al. Transplacental transfer and metabolism of buprenorphine. J. Pharmacol. Exp. Ther. 300 1 (2002) 26-33
7. Syme M.R., Paxton J.W., and Keelan J.A. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. 43 8 (2004) 487-514
8. Aleksunes L.M., Cui Y., and Klaassen C.D. Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta. Drug Metab. Dispos. 36 9 (2008) 1960-1970
9. Chan D., et al. Placental handling of fatty acid ethyl esters: perfusion and subcellular studies. J. Pharmacol. Exp. Ther. 310 1 (2004) 75-82
10. Luck W., et al. Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. Dev. Pharmacol. Ther. 8 6 (1985) 384-395
11. Garcia-Algar O., et al. Prenatal exposure to arecoline (areca nut alkaloid) and birth outcomes. Arch. Dis. Child Fetal Neonatal Ed. 90 3 (2005) F276-F277
12. Garcia-Algar O., et al. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clin. Toxicol. (Phila.) 45 3 (2007) 295-298
13. Martin I., et al. Neonatal withdrawal syndrome after chronic maternal drinking of mate. Ther. Drug Monit. 29 1 (2007) 127-129
14. Nanovskaya T.N., et al. Methadone metabolism by human placenta. Biochem. Pharmacol. 68 3 (2004) 583-591
15. Concheiro-Guisan M., Shakleya D.M., and Huestis M.A. Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in human placenta by liquid chromatography mass spectrometry. Anal. Bioanal. Chem. 394 2 (2009) 513-522
16. Guidance for Industry, B.M.v., US Department of Health and Human Services, Food and Drug Administration, July 2009, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
17. B, I.T.Q., Validation of Analytical Procedures: Methodology, The European Agency for the Evaluation of Medicinal Products, November 1996, http://www.emea.eu.int/htms/human/ich/quality/ichfin.htm.
18. Jauniaux E., et al. Maternal tobacco exposure and cotinine levels in fetal fluids in the first half of pregnancy. Obstet. Gynecol. 93 1 (1999) 25-29
19. Pichini S., et al. Cord serum cotinine as a biomarker of fetal exposure to cigarette smoke at the end of pregnancy. Environ. Health Perspect. 108 11 (2000) 1079-1083
20. Breton C.V., et al. Prenatal tobacco smoke exposure affects global and gene-specific DNA methylation. Am. J. Respir. Crit. Care Med. 180 5 (2009) 462-467